BioTelemetry Inc (NASDAQ:BEAT) Expected to Post Earnings of $0.49 Per Share

Share on StockTwits

Wall Street brokerages expect that BioTelemetry Inc (NASDAQ:BEAT) will post earnings per share (EPS) of $0.49 for the current quarter, according to Zacks. Two analysts have provided estimates for BioTelemetry’s earnings. The lowest EPS estimate is $0.42 and the highest is $0.52. BioTelemetry posted earnings of $0.56 per share in the same quarter last year, which would suggest a negative year over year growth rate of 12.5%. The firm is scheduled to issue its next quarterly earnings report on Thursday, February 20th.

On average, analysts expect that BioTelemetry will report full-year earnings of $1.96 per share for the current financial year, with EPS estimates ranging from $1.89 to $1.99. For the next year, analysts expect that the company will report earnings of $2.06 per share, with EPS estimates ranging from $1.97 to $2.16. Zacks’ earnings per share averages are an average based on a survey of research firms that follow BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.02. BioTelemetry had a net margin of 8.98% and a return on equity of 21.77%. The company had revenue of $111.30 million for the quarter, compared to analysts’ expectations of $111.19 million. During the same quarter last year, the company posted $0.53 earnings per share. The firm’s quarterly revenue was up 11.3% on a year-over-year basis.

A number of equities analysts have recently issued reports on the company. BidaskClub upgraded BioTelemetry from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. ValuEngine upgraded BioTelemetry from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. TheStreet raised BioTelemetry from a “c+” rating to a “b-” rating in a report on Wednesday, November 20th. Finally, Lake Street Capital reissued a “buy” rating and issued a $80.00 target price (down from $90.00) on shares of BioTelemetry in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $71.83.

In other BioTelemetry news, SVP Peter Ferola sold 44,276 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total transaction of $1,728,092.28. Following the completion of the sale, the senior vice president now directly owns 19,622 shares of the company’s stock, valued at $765,846.66. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.50% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Elkfork Partners LLC increased its stake in shares of BioTelemetry by 13.1% in the 2nd quarter. Elkfork Partners LLC now owns 7,616 shares of the medical research company’s stock worth $367,000 after purchasing an additional 884 shares in the last quarter. JPMorgan Chase & Co. increased its position in BioTelemetry by 113.6% in the second quarter. JPMorgan Chase & Co. now owns 239,711 shares of the medical research company’s stock worth $11,499,000 after buying an additional 127,508 shares in the last quarter. Creative Planning purchased a new stake in BioTelemetry in the second quarter worth about $256,000. Altshuler Shaham Ltd increased its position in BioTelemetry by 55.8% in the second quarter. Altshuler Shaham Ltd now owns 4,700 shares of the medical research company’s stock worth $807,000 after buying an additional 1,683 shares in the last quarter. Finally, Logan Capital Management Inc. raised its stake in shares of BioTelemetry by 43.6% in the second quarter. Logan Capital Management Inc. now owns 154,444 shares of the medical research company’s stock worth $7,437,000 after buying an additional 46,874 shares during the period. Institutional investors and hedge funds own 94.19% of the company’s stock.

BEAT traded up $0.58 during mid-day trading on Tuesday, reaching $46.74. 281,717 shares of the company traded hands, compared to its average volume of 447,991. The company’s fifty day moving average price is $42.93 and its 200-day moving average price is $44.18. The stock has a market capitalization of $1.58 billion, a P/E ratio of 24.09, a P/E/G ratio of 2.37 and a beta of 1.32. The company has a quick ratio of 2.35, a current ratio of 2.46 and a debt-to-equity ratio of 0.51. BioTelemetry has a 52-week low of $37.07 and a 52-week high of $80.92.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Featured Story: Yield Curve

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QuickLogic  Downgraded by Zacks Investment Research to Sell
QuickLogic Downgraded by Zacks Investment Research to Sell
Regeneron Pharmaceuticals  Upgraded to “Buy” by BidaskClub
Regeneron Pharmaceuticals Upgraded to “Buy” by BidaskClub
Proofpoint  Raised to “Buy” at BidaskClub
Proofpoint Raised to “Buy” at BidaskClub
Omeros  Upgraded at BidaskClub
Omeros Upgraded at BidaskClub
360 Finance  Rating Increased to Buy at ValuEngine
360 Finance Rating Increased to Buy at ValuEngine
Kiniksa Pharmaceuticals  Downgraded by Zacks Investment Research to “Sell”
Kiniksa Pharmaceuticals Downgraded by Zacks Investment Research to “Sell”


 
© 2006-2020 Zolmax.